Biotech Values

[DewDiligence]

Re: Drug-pricing pressure and cancer-drug companies as a “sucker bet”

This whole discussion began with Dew's attempting to bolster his argument that investing in oncology-oriented small-cap biotech stocks, specifically ARIA, is a "sucker's bet."

That’s not exactly right. What I actually said (in #msg-76257542) is this:

If you define success from a commercial standpoint, your [i.e. masterlongevity’s in #msg-76257251] assertion is guaranteed. There are only so many reimbursement dollars available in the aggregate for all cancer drugs, so it’s mathematically impossible for more than a tiny percentage of these drug candidates to be commercially successful.

There are exceptions, of course; however, all told, cancer-drug candidates are a sucker bet, IMHO [emphasis newly added].

What you left out in #msg-80956091 is the qualified rather than absolute nature of my opinion on investing in cancer-drug companies.